

**REMARKS**

Reconsideration is respectfully solicited.

The Examiner has required applicants to elect species as follows:

- [1] a single polar active substance or combination of polar active substances from the list in claim 3;
- [2] a single organic alkalizing agent or combination of organic alkalizing agents from the list in claim 4;
- [3] a surfactant or combination of surfactants from the list in claim 5;
- [4] elect whether or not the composition comprises additional excipients; and
- [5] if excipient-containing compositions are elected in [4], elect a single excipient or combination of excipients listed in claim 10.

The Examiner has indicated that the species lack the same or corresponding special technical features as the species are compounds with differing chemical structures and properties and do not relate to a single general inventive concept under PCT Rule 13.1.

In response, applicants elect as follows:


- [1] the polar active substance in Claim 3 which is at least one cephalosporin including the species cephaloridine, ceftiofur, cefixime, cefepime, cefoperazone, cefotaxime, ceftazidime, and ceftriaxone. If further restriction and election was intended by the Examiner, applicants would further elect Ceftazidime.
- [2] the organic alkalizing agent of Claim 4 which has an amino acid structure;
- [3] the surfactant of Claim 5 which is at least one selected from sugar fatty acid esters;
- [4] the composition comprising additional excipients;
- [5] the composition of Claim 10 wherein the composition includes excipient(s) which is/(are) disintegrating agent(s).

Applicant(s): Chung-II HONG et al.  
Int'l Appl. No.: PCT/KR2003/002700

An early examination and allowance are respectfully solicited.

Respectfully submitted,

Date Dec 27 2007



Marina V. Schneller  
Registration No. 26,032  
VENABLE LLP  
P.O. Box 34385  
Washington, D.C. 20043-9998  
Telephone: (202) 344-4000  
Telefax: (202) 344-8300

919053